Pallas Health vs Yucca Health: brand-name or low-cost compounded options
Pallas Health vs Yucca Health compares a dual-path provider that offers FDA-approved pens and compounded preparations to a low-cost, heavily accessible compounded specialist. Early verdict: choose Pallas if you want clinician access to brand-name GLP-1s plus compounded options; choose Yucca if your priority is lower compounded monthly pricing and fast online approval.
How the two providers differ at a glance
This comparison focuses on the most distinctive supported differences: medication options, pricing structure, approval and shipping speed, payment and plan flexibility, and compounding and regulatory notes. The primary keyword Pallas Health vs Yucca Health appears here and is addressed throughout.
Medication choice and clinical routing
Pallas Health offers both FDA-approved Wegovy, Ozempic, Zepbound and Mounjaro and clinician-personalized compounded semaglutide or tirzepatide when brand medication is not the right fit. Yucca Health provides personalized compounded semaglutide and tirzepatide only, with no branded FDA-approved pens available.
Pricing and plan structure
Pallas advertises compounded semaglutide at $139 for the first month then $597 every 12 weeks, a $199 per month average, and compounded tirzepatide from $179 first month then $897 every 12 weeks, a $299 per month average. Pallas also lists cash-pay prices for brand-name pens. Yucca advertises compounded semaglutide from $146 per month and compounded tirzepatide from $258 per month, and offers 6-month plans that lower the effective monthly rate.
Approval, shipping, and state coverage
Pallas operates 100 percent online and is asynchronous in most states, with a video visit required in seven states plus Washington D.C. Pallas notes free expedited shipping. Yucca promotes an online intake with approvals typically within 24 hours, UPS 2-Day Air shipping, and licensed providers in all 50 states.
Check Yucca Health pricing and shipping
Payments, financing, and plan rules
Pallas is cash-pay only and does not bill insurance. Pallas notes FSA or HSA may require a Letter of Medical Necessity. Pallas prices its compounded plans by medication rather than by milligram, so titrating up does not raise the plan price. Yucca is also direct-pay only, does not accept insurance, but lists Buy Now Pay Later options including Klarna, Afterpay, and Affirm and a Lifetime Price Lock code that can freeze GLP-1 pricing for life when applied.
Compounding and regulatory notes
Both providers offer compounded medications and include the same regulatory caution: compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness or quality. Pallas clarifies that compounded medications are prepared by US licensed compounding pharmacies and that Pallas does not manufacture or compound medication. Yucca states medications are filled at licensed U.S. compounding pharmacies and that compounded products use the same active ingredients but are not finished FDA-approved products.
Direct comparison table
| Criteria | Pallas Health | Yucca Health |
|---|---|---|
| Medication options | FDA-approved pens plus compounded semaglutide and tirzepatide | Compounded semaglutide and tirzepatide only |
| Compounded semaglutide price | $139 first month then $597/12 weeks ($199/mo avg) | From $146 per month; 6-month plans available |
| Compounded tirzepatide price | $179 first month then $897/12 weeks ($299/mo avg) | From $258 per month |
| Approval and shipping | 100% online, asynchronous in most states; free expedited shipping | Typically 24-hour approval; UPS 2-Day Air |
| Payment options | Cash-pay only; FSA/HSA may need Letter of Medical Necessity | Cash-pay only; Klarna, Afterpay, Affirm available; Lifetime Price Lock code offered |
| State coverage | Clinician review; video required in seven states plus D.C. for intake | Licensed providers in all 50 states |
| Regulatory note | Compounded medications are not FDA-approved | Compounded medications are not FDA-approved |
What this means for you
If you want the option of branded, FDA-approved pens alongside compounded alternatives and prefer pricing that is quoted by medication rather than by dose, Pallas Health is positioned for that need. If your main priorities are the lowest per-month compounded price, fast 24-hour online approvals, BNPL financing, and explicit 6-month plan options, Yucca Health is positioned for those priorities.
Final thoughts on Pallas Health vs Yucca Health
Both platforms provide clinician-reviewed, direct-pay telehealth pathways to compounded semaglutide and tirzepatide, and both include the regulatory caution that compounded medications are not FDA-approved. Pallas adds access to branded FDA-approved GLP-1 pens and a plan price that does not rise with titration. Yucca focuses on lower advertised compounded monthlies, rapid approvals, nationwide provider licensing, and financing options. Use the comparison above to match the provider to your priorities.
Choose Pallas Health if you want clinician access to both FDA-approved brand-name pens and clinician-personalized compounded preparations, prefer a single plan price that does not increase with dose titration, and value free expedited shipping.
Choose Yucca Health if you prioritize lower advertised compounded monthly pricing, fast 24-hour approvals, UPS 2-Day Air shipping, nationwide licensed providers, and Buy Now Pay Later payment options.